Wedbush Maintains Outperform on Kura Oncology, Lowers Price Target to $36
Wedbush analyst Robert Driscoll maintains Kura Oncology (NASDAQ:KURA) with a Outperform and lowers the price target from $38 to $36.
Login to comment